BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31897332)

  • 1. Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in
    Yoon KH; Chae S; Kang E; Shin HC; Kim JH; Kim IA; Park SY; Kim SW; Kim EK
    J Breast Cancer; 2019 Dec; 22(4):587-598. PubMed ID: 31897332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
    Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.
    Cao W; Xie Y; He Y; Li J; Wang T; Fan Z; Fan T; Ouyang T
    Breast Cancer Res Treat; 2019 Jun; 175(3):749-754. PubMed ID: 30895535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer?
    Garcia-Etienne CA; Barile M; Gentilini OD; Botteri E; Rotmensz N; Sagona A; Farante G; Galimberti V; Luini A; Veronesi P; Bonanni B
    Ann Surg Oncol; 2009 Dec; 16(12):3380-7. PubMed ID: 19649554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.
    Allué Cabañuz M; Domingo Bretón M; Chóliz Ezquerro J; Arribas Del Amo MD; Güemes Sánchez AT
    Cir Esp (Engl Ed); 2020 Dec; 98(10):612-617. PubMed ID: 32505558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.
    Akdeniz D; van Barele M; Heemskerk-Gerritsen BAM; Steyerberg EW; Hauptmann M; ; van de Beek I; van Engelen K; Wevers MR; Gómez García EB; Ausems MGEM; Berger LPV; van Asperen CJ; Adank MA; Collée MJ; Stommel-Jenner DJ; Jager A; Schmidt MK; Hooning MJ
    Breast; 2022 Feb; 61():98-107. PubMed ID: 34929424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
    Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
    Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Ipsilateral and Contralateral Cancer in BRCA Mutation Carriers with Breast Cancer.
    Green L; Meric-Bernstam F
    Curr Breast Cancer Rep; 2011 Sep; 3(3):151-155. PubMed ID: 24587872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for
    Sun J; Chu F; Pan J; Zhang Y; Yao L; Chen J; Hu L; Zhang J; Xu Y; Wang X; Cao W; Xie Y
    J Clin Oncol; 2023 Feb; 41(5):991-999. PubMed ID: 36480783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
    Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
    J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
    Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
    Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations.
    Turner BC; Harrold E; Matloff E; Smith T; Gumbs AA; Beinfield M; Ward B; Skolnick M; Glazer PM; Thomas A; Haffty BG
    J Clin Oncol; 1999 Oct; 17(10):3017-24. PubMed ID: 10506595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
    J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients.
    Lin PH; Chen SC; Tseng LM; Chang KJ; Huang AC; Cheng KC; Yang K; Wu HC; Chao TY; Chang YC; Lin PC; Kuo WH; Kuo WL; Lin CH; Chen HM; Yeh DC; Liu LC; Liu CY; Wang MY; Lo C; Lu YS; Huang CS
    Breast Cancer Res Treat; 2022 Apr; 192(3):629-637. PubMed ID: 35113257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation.
    Ye F; Huang L; Lang G; Hu X; Di G; Shao Z; Cao A
    Cancer Med; 2020 Mar; 9(5):1903-1910. PubMed ID: 31912664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study.
    Kang E; Jung JJ; Lim C; Kim HK; Lee HB; Han W; Moon HG
    Breast Cancer Res; 2024 Jan; 26(1):14. PubMed ID: 38254240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.